检测前列腺癌中雄激素受体辅助调节因子160的表达及临床意义

目的检测雄激素受体辅助因子(ARA)160在前列腺癌组织和良性前列腺增生标本中的表达情况,分析其与患者的临床病理特征Gleason评分、临床分期、前列腺特异抗原(PSA)]之间的相关性。方法应用实时定量聚合酶链反应(RT-PCR)(SYBR染料法)技术和免疫组织化学技术,对前列腺癌组织和良性前列腺增生标本中ARA160的表达进行研究。结果良性前列腺增生患者和前列腺癌患者标本中ARA160mRNA均有表达,良性组织中表达量高于前列腺癌组织中的表达,且随着癌组织分期增高ARA160的表达水平降低;Gleason评分≤7分的癌组织比Gleason评分>7分的癌组织表达量高;内分泌治疗有效患者的癌组织比治疗无效患者的癌组织表达量高。结论 ARA160的表达在正常组织中高于癌组织,且与患者的临床特征(Gleason评分、临床分期)显著相关,肿瘤分期越早、Gleason评分≤7分及内分泌治疗有效的患者其ARA160mRNA的表达量越高。ARA160可能是前列腺癌预后的一个良好预测指标,对于指导前列腺癌内分泌治疗有一定的意义。

Expression of ARA160 in prostate carcinoma and its significance

Objective To detect the expression of ARA160 in the prostate carcinoma tissues and benign prostate hyperplasia(BPH) tissues and to explore the relationship between the expression of ARA160 and the clinical significance.Methods Immunohistochemistry was used to examine the expression of ARA160 in the samples of the prostate carcinoma tissues and BPH tissues.Results ARA160 expressed in both the samples of the prostate carcinoma tissues and BPH tissues.The expressions of ARA160 in BPH tissues were more than those of prostate cancer tissues.The expressions of the cancer tissues with Gleason score≤7 are more than those of with Gleason score>7.The expressions of the cancer tissues with A/B phase are more than those of with C/D phase.The expressions of the cancer tissues with effective endocrine therapy are more than those of with ineffective endocrine therapy.Conclusion ARA160 expression is significantly correlated with the clinical characteristics of the patient.And ARA160 can be regarded as a prognostic molecular marker for prostate carcinoma as well as a predictor of endocrinologically therapeutic effect on the disease.